Developer docs
API playgroundTry for free, no card

Search company profiles

Genesys Capital

Full company profile

uuid0002d58

Namestring
Genesys Capital
Legal namestring
Genesys Capital
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Genesys Capital is a Toronto-based life sciences venture capital firm founded in 2000 by Damian Lamb and Kelly Holman. The firm invests exclusively in early-stage biotechnology, pharmaceutical, and medical technology companies across North America, with deep operational ties to Canadian research institutions including McMaster University, the University of Toronto, and Queen's University. Genesys employs a create-and-build strategy, acting as founding investor in approximately 80% of its deals and assuming active board roles through the company-building phase; it has backed 44 portfolio companies and recorded 20 exits, headlined by Fusion Pharmaceuticals (acquired by AstraZeneca for $2.4 billion USD) and Inversago Pharma (acquired by Novo Nordisk for $1.1 billion USD).

The firm's core offering is not a technology product but a specialized investment service combining capital deployment with strategic guidance, board leadership, and operational support to scientific founders. Revenue is generated through three mechanics typical of closed-end venture funds: (1) management fees on committed and deployed capital across its five funds, which together exceed $400 million in aggregate raises; (2) carried interest on profitable exits, of which the firm has realized at least 20; and (3) fund-raising proceeds from limited partners for successive vehicles, with Genesys Ventures IV (closed mid-2025) representing the largest fund to date. Recent lead investments include a $10.3M Series B1 in Enspire DBS Therapy (Jan 2026), a $21M co-led Series B in Feldan Therapeutics (Sep 2024), and a CAD $7.3M seed in Antegrade Medical (Oct 2025).

Genesys serves a single primary customer segment — clinical-stage and early-stage life sciences companies seeking growth capital and strategic partnership — and distributes capital exclusively through direct equity investment, typically as founding investor or lead investor in Series A rounds. The firm maintains a small, senior team of approximately nine professionals based at its Toronto headquarters, and pursues a regional North American investment thesis anchored in proximity to the Ontario research corridor.

Short descriptiontext

Genesys Capital is a Toronto-based life sciences venture capital firm founded in 2000 that invests as founding or lead investor in early-stage biotechnology, pharmaceutical, and medical technology companies across North America, having raised over $400 million across five funds and executed 20 exits.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences venture capital, biotechnology investing, early-stage healthcare funds, medical technology financing, pharmaceutical venture investing
Industry3 codes
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAC
Late-Stage Venture Capital (Series C+)
NAICS code3 codes
  • Funds, Trusts, and Other Financial Vehicles525
  • Other Financial Vehicles525990
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital - Life Sciences
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Capital Returns
TypeLicensing Royalties
Description

Genesys Capital generates returns through successful portfolio company exits (acquisitions and IPOs), management fees from venture capital funds, and carried interest on investment profits. The firm has achieved over 20 exits including major acquisitions like Fusion Pharmaceuticals (AstraZeneca, $2.4B) and Inversago Pharma (Novo Nordisk, $1.1B).

genesyscapital.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Genesys Capital is a life sciences venture capital firm that invests in early-stage biotechnology, pharmaceuticals, and medical technology companies as a founding or lead investor in Series A rounds. The firm deploys capital from its venture funds (currently Genesys Ventures IV), provides strategic guidance, board leadership, and operational support to scientific founders, and has invested in 44 companies across its 25+ year history. It generates returns through portfolio company exits, including notable acquisitions such as Fusion Pharmaceuticals by AstraZeneca ($2.4B) and Inversago Pharma by Novo Nordisk ($1.1B).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 20 successful exits achieved
+2 more records
Product overview1 text field

Genesys Capital is a life science venture capital firm that invests in early-stage biotechnology, pharmaceuticals, and medical technology companies. As a VC firm, it does not offer traditional products or services in the SaaS sense; instead, it provides investment capital, strategic guidance, and operational support to portfolio companies. The firm has raised over $400 million across 5 early-stage venture funds, with 44 portfolio companies and 20 exits.

Product and service2 records
1Genesys Ventures IV LP
CategoryEarly-stage Life Sciences Venture Capital Fund
Description

Genesys Ventures IV LP is Genesys Capital's largest early-stage life sciences venture capital fund to date, from which the firm is currently investing into North American biotechnology, pharmaceutical, and medical technology companies as founding or lead investor in Series A rounds. Intended for limited partners seeking exposure to early-stage life sciences venture capital.

2Genesys Ventures I–III (Prior Early-Stage Venture Funds)
CategoryEarly-stage Life Sciences Venture Capital Fund
Description

Earlier Genesys Capital venture funds (Funds I–III) that deployed capital into North American early-stage biotechnology, pharmaceutical, and medical technology companies. Together with Fund IV, these funds constitute the firm's $400M+ raised across five early-stage venture funds. Intended for limited partners and institutional investors in life sciences venture capital.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Damian Lamb serves on the Board of the Centre for Probe Development and Commercialization at McMaster University, representing the firm's ongoing relationship with academic commercialization entities.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Jamie Stiff serves as an advisor to OGI, supporting genomics research commercialization in Ontario.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Jamie Stiff serves as an advisor to CCRM, supporting commercialization of regenerative medicine technologies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Jamie Stiff serves as an advisor to Medicine by Design, supporting stem cell and regenerative medicine research translation.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Jamie Stiff serves as an associate with CDL, supporting early-stage company development and mentorship.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Jamie Stiff volunteers as a board member for BioteCanada, the national industry association for biotechnology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Canadian-headquartered venture capital firm investing in early-stage life sciences companies. Directly comparable in terms of fund size, geography, and create-and-build approach in biotech and medtech.

TypeDirect peer
Description

Toronto-based life sciences venture capital firm with a similar focus on early-stage Canadian biotech and medtech companies. Overlapping investment theses and LP base with Genesys Capital.

3Amplitude Ventures
TypeDirect peer
Description

Canadian life sciences venture firm focused on precision medicine and earlier-stage biotech. Comparable in size, mandate, and Canadian academic sourcing network.

TypeBroad incumbent
Description

Established North American life sciences venture capital firm with a broader platform across biotech, medtech, and healthcare services. Comparable sector focus but materially larger fund sizes.

TypeBroad incumbent
Description

U.S. life sciences venture firm with similar early-stage biotech focus, including company formation out of academic research. Comparable origination strategy but larger fund scale.

TypeBroad incumbent
Description

Boston-based life sciences VC with a create-and-build model for early-stage biotech companies. Closest comparable peer in approach and stage; operates at a larger fund size.

TypeBroad incumbent
Description

One of the largest dedicated healthcare investment firms globally, investing across all stages of biotech, medtech, and healthcare services. Provides scale and stage benchmarks for the broader sector.

TypeEmerging player
Description

Strategic venture arm of Alexandria Real Estate Equities, active in early-stage life sciences with strong academic sourcing in North America. Comparable origination profile with a different capital structure.

TypeRegional player
Description

Canadian healthcare-specialized investment bank and venture capital firm. Adjacent rather than direct overlap, but shares the Canadian life sciences ecosystem and similar founder relationships.

TypeEmerging player
Description

Healthcare-focused VC that co-invested with Genesys in Antegrade Medical. Comparable early-stage medtech orientation with their Medtech Ventures fund.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment38 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genesys Capital

Venture Capital - Life Sciencesgenesyscapital.com

Genesys Capital is a Toronto-based life sciences venture capital firm founded in 2000 that invests as founding or lead investor in early-stage biotechnology, pharmaceutical, and medical technology companies across North America, having raised over $400 million across five funds and executed 20 exits.

What Genesys Capital does

Genesys Capital is a Toronto-based life sciences venture capital firm founded in 2000 by Damian Lamb and Kelly Holman. The firm invests exclusively in early-stage biotechnology, pharmaceutical, and medical technology companies across North America, with deep operational ties to Canadian research institutions including McMaster University, the University of Toronto, and Queen's University. Genesys employs a create-and-build strategy, acting as founding investor in approximately 80% of its deals and assuming active board roles through the company-building phase; it has backed 44 portfolio companies and recorded 20 exits, headlined by Fusion Pharmaceuticals (acquired by AstraZeneca for $2.4 billion USD) and Inversago Pharma (acquired by Novo Nordisk for $1.1 billion USD).

The firm's core offering is not a technology product but a specialized investment service combining capital deployment with strategic guidance, board leadership, and operational support to scientific founders. Revenue is generated through three mechanics typical of closed-end venture funds: (1) management fees on committed and deployed capital across its five funds, which together exceed $400 million in aggregate raises; (2) carried interest on profitable exits, of which the firm has realized at least 20; and (3) fund-raising proceeds from limited partners for successive vehicles, with Genesys Ventures IV (closed mid-2025) representing the largest fund to date. Recent lead investments include a $10.3M Series B1 in Enspire DBS Therapy (Jan 2026), a $21M co-led Series B in Feldan Therapeutics (Sep 2024), and a CAD $7.3M seed in Antegrade Medical (Oct 2025).

Genesys serves a single primary customer segment — clinical-stage and early-stage life sciences companies seeking growth capital and strategic partnership — and distributes capital exclusively through direct equity investment, typically as founding investor or lead investor in Series A rounds. The firm maintains a small, senior team of approximately nine professionals based at its Toronto headquarters, and pursues a regional North American investment thesis anchored in proximity to the Ontario research corridor.

Genesys Capital firmographics

Firmographics
Name
Genesys Capital
Legal name
Genesys Capital
Website
https://genesyscapital.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
11–50 employees
Short description
Genesys Capital is a Toronto-based life sciences venture capital firm founded in 2000 that invests as founding or lead investor in early-stage biotechnology, pharmaceutical, and medical technology companies across North America, having raised over $400 million across five funds and executed 20 exits.
Ownership category
akta.pro rank

Genesys Capital industry classification

Industry
Product category
Venture Capital - Life Sciences
NAICS
Funds, Trusts, and Other Financial Vehicles (525), Other Financial Vehicles (525990), Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAC
Late-Stage Venture Capital (Series C+)

Keywords

  • Life sciences venture capital
  • Biotechnology investing
  • Early-stage healthcare funds
  • Medical technology financing
  • Pharmaceutical venture investing

Where Genesys Capital is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Genesys Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations

Revenue model

  1. Venture Capital Returns: Genesys Capital generates returns through successful portfolio company exits (acquisitions and IPOs), management fees from venture capital funds, and carried interest on investment profits. The firm has achieved over 20 exits including major acquisitions like Fusion Pharmaceuticals (AstraZeneca, $2.4B) and Inversago Pharma (Novo Nordisk, $1.1B).

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Genesys Capital product offering

Product offering

Core offering

Genesys Capital is a life sciences venture capital firm that invests in early-stage biotechnology, pharmaceuticals, and medical technology companies as a founding or lead investor in Series A rounds. The firm deploys capital from its venture funds (currently Genesys Ventures IV), provides strategic guidance, board leadership, and operational support to scientific founders, and has invested in 44 companies across its 25+ year history. It generates returns through portfolio company exits, including notable acquisitions such as Fusion Pharmaceuticals by AstraZeneca ($2.4B) and Inversago Pharma by Novo Nordisk ($1.1B).

Product overview

Genesys Capital is a life science venture capital firm that invests in early-stage biotechnology, pharmaceuticals, and medical technology companies. As a VC firm, it does not offer traditional products or services in the SaaS sense; instead, it provides investment capital, strategic guidance, and operational support to portfolio companies. The firm has raised over $400 million across 5 early-stage venture funds, with 44 portfolio companies and 20 exits.

Differentiator

Problem solved

Functional benefit

Products and services

  • Genesys Ventures IV LP Genesys Ventures IV LP is Genesys Capital's largest early-stage life sciences venture capital fund to date, from which the firm is currently investing into North American biotechnology, pharmaceutical, and medical technology companies as founding or lead investor in Series A rounds. Intended for limited partners seeking exposure to early-stage life sciences venture capital.
  • Genesys Ventures I–III (Prior Early-Stage Venture Funds) Earlier Genesys Capital venture funds (Funds I–III) that deployed capital into North American early-stage biotechnology, pharmaceutical, and medical technology companies. Together with Fund IV, these funds constitute the firm's $400M+ raised across five early-stage venture funds. Intended for limited partners and institutional investors in life sciences venture capital.

Quantifiable outcome

  • 20 successful exits achieved
  • +2 more outcomes

Companies that use Genesys Capital

Customer profile

Segments1 record

Ideal customer profiles1 record

Genesys Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Genesys Capital partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor.

  • Centre for Probe Development and Commercialization at McMaster UniversityminorStrategic or Co-development PartnerDamian Lamb serves on the Board of the Centre for Probe Development and Commercialization at McMaster University, representing the firm's ongoing relationship with academic commercialization entities.
  • Ontario Genomics Institute (OGI)minorStrategic or Co-development PartnerJamie Stiff serves as an advisor to OGI, supporting genomics research commercialization in Ontario.
  • Centre for Commercialization of Regenerative Medicine (CCRM)minorStrategic or Co-development PartnerJamie Stiff serves as an advisor to CCRM, supporting commercialization of regenerative medicine technologies.
  • Medicine by DesignminorStrategic or Co-development PartnerJamie Stiff serves as an advisor to Medicine by Design, supporting stem cell and regenerative medicine research translation.
  • Creative Destruction Lab (CDL)minorStrategic or Co-development PartnerJamie Stiff serves as an associate with CDL, supporting early-stage company development and mentorship.
  • BioteCanadaminorStrategic or Co-development PartnerJamie Stiff volunteers as a board member for BioteCanada, the national industry association for biotechnology.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Genesys Capital competitors and assessment

Company assessment

Direct peers

  • TVM Life Science Ventures: Canadian-headquartered venture capital firm investing in early-stage life sciences companies. Directly comparable in terms of fund size, geography, and create-and-build approach in biotech and medtech.
  • Lumira Ventures: Toronto-based life sciences venture capital firm with a similar focus on early-stage Canadian biotech and medtech companies. Overlapping investment theses and LP base with Genesys Capital.
  • Amplitude Ventures: Canadian life sciences venture firm focused on precision medicine and earlier-stage biotech. Comparable in size, mandate, and Canadian academic sourcing network.

Broad incumbents

  • Versant Ventures: Established North American life sciences venture capital firm with a broader platform across biotech, medtech, and healthcare services. Comparable sector focus but materially larger fund sizes.
  • 5AM Ventures: U.S. life sciences venture firm with similar early-stage biotech focus, including company formation out of academic research. Comparable origination strategy but larger fund scale.
  • Atlas Venture: Boston-based life sciences VC with a create-and-build model for early-stage biotech companies. Closest comparable peer in approach and stage; operates at a larger fund size.
  • OrbiMed: One of the largest dedicated healthcare investment firms globally, investing across all stages of biotech, medtech, and healthcare services. Provides scale and stage benchmarks for the broader sector.

Emerging players

  • Alexandria Venture Investments: Strategic venture arm of Alexandria Real Estate Equities, active in early-stage life sciences with strong academic sourcing in North America. Comparable origination profile with a different capital structure.
  • Sectoral Asset Management: Healthcare-focused VC that co-invested with Genesys in Antegrade Medical. Comparable early-stage medtech orientation with their Medtech Ventures fund.

Regional players

  • Bloom Burton & Co. Canadian healthcare-specialized investment bank and venture capital firm. Adjacent rather than direct overlap, but shares the Canadian life sciences ecosystem and similar founder relationships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Genesys Capital social profiles

Digital presence

Genesys Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genesys Capital leadership team

Management profile

Number of profiles

Profiles8 records

Genesys Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genesys Capital M&A and investment

M&A and investment

M&A

Investments38 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genesys Capital

What does Genesys Capital do?

Genesys Capital is a life sciences venture capital firm that invests in early-stage biotechnology, pharmaceuticals, and medical technology companies as a founding or lead investor in Series A rounds. The firm deploys capital from its venture funds (currently Genesys Ventures IV), provides strategic guidance, board leadership, and operational support to scientific founders, and has invested in 44 companies across its 25+ year history. It generates returns through portfolio company exits, including notable acquisitions such as Fusion Pharmaceuticals by AstraZeneca ($2.4B) and Inversago Pharma by Novo Nordisk ($1.1B).

Is Genesys Capital a public or private company?

Genesys Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Genesys Capital founded?

Genesys Capital was founded in 2000. It employs 11 to 50 people.

Where is Genesys Capital based?

Genesys Capital is headquartered in Toronto, Canada, in the North America region.

How does Genesys Capital make money?

One revenue line is on record: venture Capital Returns.

Who are Genesys Capital's main competitors?

Direct peers on record are TVM Life Science Ventures, Lumira Ventures and Amplitude Ventures. Broad incumbents are Versant Ventures, 5AM Ventures, Atlas Venture and OrbiMed. Emerging players are Alexandria Venture Investments and Sectoral Asset Management. Bloom Burton & Co. is listed as a regional player.

Does Genesys Capital have an API?

No public API is recorded for Genesys Capital.

What industry is Genesys Capital in?

Genesys Capital's product category is Venture Capital - Life Sciences. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 525 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Genesys Capital Expands University Seed Fund With Sunnybrook And UHNGenesys Capital closed the second round of its University Seed Fund, adding Sunnybrook Health Sciences Centre and University Health Network as hospital partners. The fund targets pre-seed and seed investments in Canadian life sciences startups, with partners including the University of Toronto, McMaster, and Venture Ontario. The addition strengthens connections to Toronto's research and healthcare ecosystem.Private Capital JournalGenesys Capital holds 2nd close for Genesys University Seed FundGenesys Capital closed the second round of its Genesys University Seed Fund, adding Sunnybrook Health Sciences Centre and University Health Network as hospital partners. The fund targets pre-seed and seed rounds for life science companies from Canadian universities and hospitals, aiming to address early-stage capital shortages. The partnership strengthens pathways from discovery to commercialization in Canada's life sciences sector.Startup ResearcherGenesys Capital Welcomes Sunnybrook and UHN to University Seed FundGenesys Capital closed its second round of the Genesys University Seed Fund, adding Sunnybrook Health Sciences Centre and University Health Network as hospital partners. The fund invests in pre-seed and seed rounds for life science companies from Canadian universities and hospitals. The partnership aims to bridge the early-stage capital gap and support commercialization of Canadian innovations.Pulse 2.0Genesys University Seed Fund Holds First Close With Over $30 Million In CommitmentsThe University of Toronto, McMaster University, Venture Ontario, and Genesys Capital announced the creation of the Genesys University Seed Fund, a new early-stage life sciences venture capital fund that has held its first close with over $30 million in commitments. The fund aims to address a capital gap for Ontario life sciences startups by supporting the translation of university-based research into companies, with a goal to reach $40 million and prevent promising firms from relocating to Boston or Silicon Valley. The fund will be managed by Genesys Capital, which has invested over $400 million in the sector over 25 years, with returns from university limited partners directed back into research and innovation.BetaKitOntario gets new fund to back university life sciences spinoutsThe University of Toronto, McMaster University, and the Ontario government have launched the Genesys University Seed Fund, a $40-million venture capital fund targeting seed-stage life sciences spinouts from both institutions and partner hospitals. The fund has already secured a first close of more than $30 million CAD from limited partners including the two universities, Venture Ontario, the Temerty Group, and RBC, with Genesys Capital managing the fund. The initiative aims to address a critical funding gap that has caused promising Canadian innovators to relocate to Boston or Silicon Valley, targeting investments of up to $1 million in 10 to 15 startups.Mirage NewsU of T, McMaster Launch Life Sciences Fund with GenesysThe University of Toronto and McMaster University have partnered with Venture Ontario and Genesys Capital to launch the Genesys University Seed Fund, a new life sciences venture capital fund targeting early-stage startups in Ontario. The fund has held a first close representing over $30 million in commitments, addressing a critical gap where Canadian life sciences innovators historically lacked domestic early-stage investment capital and often relocated to the US. The fund will be managed by Genesys Capital, which has over $400 million invested over 25 years, with returns from U of T and McMaster directed back to support further university research.Financial PostU of T, McMaster Announce Early-Stage Life Sciences Venture Fund With Genesys CapitalThe University of Toronto, McMaster University, and Venture Ontario announced a partnership with veteran investor Genesys Capital to create the Genesys University Seed Fund, a new early-stage life sciences venture capital fund for Ontario. The fund has achieved a first close representing over $30 million in commitments and is targeting a fund size of up to $40 million, with the aim of preventing Canadian life sciences innovators from relocating to jurisdictions like Boston and Silicon Valley. Returns on investments from the universities will be reinvested to support further research and innovation, creating a self-sustaining cycle for Ontario's life sciences ecosystem.Business Wire BlogU of T, McMaster Announce Early-Stage Life Sciences Venture Fund With Genesys CapitalThe University of Toronto, McMaster University, Venture Ontario, and Genesys Capital have launched the Genesys University Seed Fund, a life sciences venture capital fund designed to provide early-stage capital to Ontario startups and prevent promising researchers from relocating to the US. The fund has completed a first close with over $30 million in commitments and is targeting up to $40 million in total size. Returns on university investments will be reinvested into further research, creating a self-sustaining cycle of innovation and economic growth across Ontario's life sciences sector.UtorontoU of T, together with McMaster, announces early-stage life sciences venture fund with Genesys CapitalThe University of Toronto has partnered with McMaster University, Venture Ontario, and veteran investor Genesys Capital to create the Genesys University Seed Fund, a life sciences venture capital fund that will provide early-stage capital for startups in Ontario. The fund has held a first close representing over $30 million of commitments and is targeting up to $40 million in total size. The initiative aims to address a critical gap in early-stage investment capital that has caused many Canadian life sciences innovators to relocate to the US, following similar models at MIT, Harvard, and other American universities.Business Wire BlogGenesys Capital Announces Second Close of Genesys University Seed Fund, Welcoming Sunnybrook and UHN as Hospital PartnersGenesys Capital announced the second close of its Genesys University Seed Fund, welcoming Sunnybrook Health Sciences Centre and University Health Network as hospital partners. The fund invests in pre-seed and seed rounds for life science companies emerging from Canadian universities and hospitals, aiming to address a shortage of early-stage capital.